The First Amendment does not protect a drug manufacturer’s communications when the speech at issue could reduce the value of another company’s exclusivity, two pharmaceutical companies say.
In separate comments on an FDA draft guidance about medical product communications that are consistent with labeling, Daiichi Sankyo Co. Ltd. and AbbVie Inc